United Therapeutics
$541.70Change from previous close: −5.19%Absolute change: −$29.68
At a glance
- Revenue growth
- +10.61%
- 2025 vs 2024
- Net income growth
- +11.68%
- 2025 vs 2024
- Net margin
- 41.9%
- 2024: 41.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 7,880 | 7,364 | 7,167 | 6,045 | — |
| Current assets | 3,703 | 3,874 | 3,551 | 3,380 | — |
| Cash and equivalents | 1,557 | 1,697 | 1,208 | 961 | — |
| Short-term investments | 1,363 | 1,570 | 1,786 | 1,878 | — |
| Receivables | 350 | 279 | 279 | 220 | — |
| Inventory | 183 | 158 | 112 | 102 | — |
| Net property, plant and equipment | 1,730 | 1,222 | 1,045 | 862 | — |
| Goodwill | 32.3 | 32.3 | 33.7 | 28.0 | — |
| Other intangible assets | 84.2 | 79.6 | 80.5 | 16.5 | — |
| Long-term investments | 1,777 | 1,475 | 1,910 | 1,316 | — |
| Current liabilities | 561 | 738 | 804 | 343 | — |
| Accounts payable | 7.1 | 6.0 | 5.6 | 4.1 | — |
| Long-term debt | — | — | 300 | 800 | 800 |
| Total debt | — | 300 | 700 | 800 | 800 |
| Total liabilities | 784 | 920 | 1,182 | 1,248 | — |
| Total equity (incl. minority) | 7,096 | 6,444 | 5,985 | 4,797 | — |
| Retained earnings | 8,557 | 7,222 | 6,027 | 5,042 | — |